1. Volume 113, Issue 10, Pages 1695-1705.e6 (October 2006)
Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy 
Robert L. Avery, MD, Joel Pearlman, MD, PhD, Dante J. Pieramici, MD, Melvin D. Rabena, BS, Alessandro A. Castellarin, MD, Ma’an A. Nasir, MD, Matthew J. Giust, CRA, Robert Wendel, MD, Arun Patel, MD 
Ophthalmology 
Volume 113, Issue 10, Pages e6 (October 2006)
DOI: /j.ophtha
Copyright © 2006 American Academy of Ophthalmology Terms and Conditions

2. Figure 1
Case 3. Color, midphase, and late-phase fluorescein angiograms and iris angiograms at (A) baseline and (B) 1 week after intravitreal injection of 1.25 mg of bevacizumab.
Ophthalmology  , e6DOI: ( /j.ophtha )
Copyright © 2006 American Academy of Ophthalmology Terms and Conditions

3. Figure 2
Case 13A. Red-free (A), midphase (B), and late-phase (C) angiograms at baseline and red-free (D), midphase (E), and late-phase (F) angiograms 1 week after intravitreal injection of 1.25 mg of bevacizumab.
Ophthalmology  , e6DOI: ( /j.ophtha )
Copyright © 2006 American Academy of Ophthalmology Terms and Conditions

4. Figure 3
Case 20A. Red-free, midphase, and late-phase fluorescein angiograms and iris angiograms at (A) baseline and (B) 1 week after intravitreal injection of 1.25 mg of bevacizumab.
Ophthalmology  , e6DOI: ( /j.ophtha )
Copyright © 2006 American Academy of Ophthalmology Terms and Conditions

5. Figure 4
Case 20B. Red-free, midphase, and late-phase fluorescein angiograms at (A) baseline and (B) 1 week after intravitreal injection of 125 μg of bevacizumab.
Ophthalmology  , e6DOI: ( /j.ophtha )
Copyright © 2006 American Academy of Ophthalmology Terms and Conditions

6. Figure 5
Case 27. Red-free (A), midphase (B), and late-phase (C) angiograms at baseline and red-free (D), midphase (E), and late-phase (F) angiograms 3 weeks after intravitreal injection of 1.25 mg of bevacizumab.
Ophthalmology  , e6DOI: ( /j.ophtha )
Copyright © 2006 American Academy of Ophthalmology Terms and Conditions

7. Figure 6
Case 19A. Red-free and midphase fluorescein angiograms of the optic nerve and temporal midperiphery and late-phase fluorescein angiogram at (A) baseline; (B) 1 week after intravitreal injection of 12.5 μg of bevacizumab; (C) 4 weeks after initial injection, at which time 1.25 mg was reinjected; and (D) 1 day after the second injection.
Ophthalmology  , e6DOI: ( /j.ophtha )
Copyright © 2006 American Academy of Ophthalmology Terms and Conditions

8. Figure 7
Case 6A. Fluorescein angiogram montage before treatment showing extensive neovascularization and macular edema.
Ophthalmology  , e6DOI: ( /j.ophtha )
Copyright © 2006 American Academy of Ophthalmology Terms and Conditions

9. Figure 8
Case 6A. Fluorescein angiogram montage 1 week after injection of 1.25 mg of bevacizumab showing reduction in the leakage of neovascularization and macular edema.
Ophthalmology  , e6DOI: ( /j.ophtha )
Copyright © 2006 American Academy of Ophthalmology Terms and Conditions

10. Figure 9
Case 6A. Fluorescein angiogram montage 2 weeks after injection of 1.25 mg of bevacizumab showing a partial return in the leakage of neovascularization and macular edema.
Ophthalmology  , e6DOI: ( /j.ophtha )
Copyright © 2006 American Academy of Ophthalmology Terms and Conditions

11. Figure 10
Case 14A. Midphase and late-phase fluorescein angiograms at (A, B) baseline and (C, D) 6 weeks after intravitreal injection of 1.25 mg of bevacizumab.
Ophthalmology  , e6DOI: ( /j.ophtha )
Copyright © 2006 American Academy of Ophthalmology Terms and Conditions

12. Figure 11
Case 14A. Horizontal and vertical optical coherence tomography images at (A, B) baseline and (C, D) 6 weeks after intravitreal injection of 1.25 mg of bevacizumab.
Ophthalmology  , e6DOI: ( /j.ophtha )
Copyright © 2006 American Academy of Ophthalmology Terms and Conditions

13. Figure 12
Case 14A. Iris angiograms of the left eye (A–C) and right eye (D–F). At baseline, there is mild iris neovascularization in the left eye (A), for which an injection of 1.25 mg of bevacizumab was given, and there is florid iris neovascularization in the fellow right eye (D). Four weeks later, the iris neovascularization in the injected left eye has resolved (B), and there is a suggestion that there is less leakage in the fellow right eye (E), which was then injected with 1.25 mg of bevacizumab. Six weeks after the injection for the left eye, there is no recurrence (C). The leakage in the right eye (F) partially resolved 2 weeks after it received an injection.
Ophthalmology  , e6DOI: ( /j.ophtha )
Copyright © 2006 American Academy of Ophthalmology Terms and Conditions

14. Figure 13
Case 12. Regression of neovascularization of the disc in the fellow untreated eye. At baseline, a fluorescein angiogram demonstrates (A) active areas of neovascularization elsewhere in the right eye and (B) neovascularization of the disc in the left eye. One week after intravitreal injection of 1.25 mg of bevacizumab in the right eye, there are (C) complete resolution of the leakage in the right eye and (D) a reduction in the leakage in the untreated left eye. Two weeks after injection in the right eye, the neovascularization (E) remains undetectable in the right eye but (F) recurs in the fellow untreated eye.
Ophthalmology  , e6DOI: ( /j.ophtha )
Copyright © 2006 American Academy of Ophthalmology Terms and Conditions

15. Figure 14
Case 12. Baseline neovascularization of the disc in the fellow untreated eye. Top, Color and red-free images before injection of the fellow eye. Bottom, Midphase and late-phase fluorescein angiograms demonstrating leakage of neovascularization of the disc.
Ophthalmology  , e6DOI: ( /j.ophtha )
Copyright © 2006 American Academy of Ophthalmology Terms and Conditions

16. Figure 15
Case 12. Resolution of neovascularization of the disc in the fellow untreated eye. Top, Color and red-free images 1 week after injection of 1.25 mg of bevacizumab to the fellow eye. Bottom, Midphase and late-phase fluorescein angiograms demonstrating resolution of neovascularization of the disc leakage in this eye after injection of the fellow eye.
Ophthalmology  , e6DOI: ( /j.ophtha )
Copyright © 2006 American Academy of Ophthalmology Terms and Conditions

17. Figure 16
Case 22. Mid-phase fluorescein angiograms of (A) superior and (B) temporal midperiphery at baseline and (C, D) 1 week after intravitreal injection of 62.5 μg of bevacizumab.
Ophthalmology  , e6DOI: ( /j.ophtha )
Copyright © 2006 American Academy of Ophthalmology Terms and Conditions

18. Figure 17
Case 30. Midphase and late-phase fluorescein angiograms at (A) baseline and (B) 1 week after intravitreal injection of 6.2 μg of bevacizumab. A reduction in leakage of neovascularization of the disc is noted.
Ophthalmology  , e6DOI: ( /j.ophtha )
Copyright © 2006 American Academy of Ophthalmology Terms and Conditions

19. Figure 18
Case 32. Montage color photographs (left) at baseline and (right) 1 week after intravitreal injection of 1.25 mg of bevacizumab. There is a reduction in caliber of many of the abnormal new vessels.
Ophthalmology  , e6DOI: ( /j.ophtha )
Copyright © 2006 American Academy of Ophthalmology Terms and Conditions

20. Figure 19
Case 32. Red-free, midphase, and late-phase fluorescein angiograms at (A) baseline and (B) 1 week after injection. Some large-bore abnormal vessels remain perfused after injection but are of smaller caliber and do not leak fluorescein dye. There is persistent leakage only at the optic nerve head.
Ophthalmology  , e6DOI: ( /j.ophtha )
Copyright © 2006 American Academy of Ophthalmology Terms and Conditions

21. Figure 20
Case 32. Intraoperative appearance during cutting of the dense fibrovascular tissue superior and nasal to the optic nerve head. The intraocular pressure was 20 mmHg during the cutting, yet very little bleeding was observed.
Ophthalmology  , e6DOI: ( /j.ophtha )
Copyright © 2006 American Academy of Ophthalmology Terms and Conditions